Lirafit (liraglutide biosimilar) / Glenmark - LARVOL DELTA

Effect of liraglutide biosimilar vs. reference liraglutide on weight reduction in T2DM patients with obesity: post hoc analysis of phase III trial. (PubMed, Cardiovasc Diabetol Endocrinol Rep) - "Biosimilar Liraglutide at a dose of up to 1.8 mg was non-inferior to reference Liraglutide and resulted in significant weight reduction and glycemic control (HbA1c, FPG and PPG) in Indian T2DM patients with obesity."

Journal • P3 data • Retrospective data • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Glenmark is the first to launch Biosimilar of Popular Anti-Diabetic Drug, Liraglutide, in India (PRNewswire) - "Glenmark Pharmaceuticals Ltd...has launched a biosimilar of the popular anti-diabetic drug, Liraglutide, for the first time in India. The drug is being marketed under the brand name Lirafit™ following the approval from the Drug Controller General of India (DCGI). Priced at around INR 100 for a standard dose of 1.2 mg (per day), this will lower the cost of therapy by approximately 70%, and will be available only under prescription."

Biosimilar launch • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus